Literature DB >> 22430087

Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.

Natalia Tovar1, Carlos Fernández de Larrea, Montserrat Elena, M Teresa Cibeira, Juan I Aróstegui, Laura Rosiñol, Xavier Filella, Jordi Yagüe, Joan Bladé.   

Abstract

Immunoglobulin heavy/light chain (HLC) ratios were studied in 37 patients with multiple myeloma in complete remission after autologous hematopoietic stem cell transplantation. Increased IgAκ/IgAλ and IgMκ/IgMλ ratios were associated with longer progression-free survival (P = .006 and .01, respectively). A statistical trend toward a longer overall survival was also observed for the IgAκ/IgAλ ratio (P = .068). Considering the original immunoglobulin isotype, our results indicate that an increased κ/λ ratio of the uninvolved isotype is associated with longer progression-free survival and overall survival. This is the first report demonstrating the association between the HLC ratio and sustained complete remission in patients with multiple myeloma. Our results suggest that the HLC ratio is a surrogate marker of immune recovery after myeloablative transplantation, rather than as a marker of minimal residual disease.
Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22430087     DOI: 10.1016/j.bbmt.2012.03.004

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  12 in total

Review 1.  Minimal residual disease testing after stem cell transplantation for multiple myeloma.

Authors:  A M Sherrod; P Hari; C A Mosse; R C Walker; R F Cornell
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

2.  Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.

Authors:  A Arteche-López; A Kreutzman; A Alegre; P Sanz Martín; B Aguado; M González-Pardo; M Espiño; L M Villar; D García Belmonte; R de la Cámara; C Muñoz-Calleja
Journal:  Bone Marrow Transplant       Date:  2017-04-03       Impact factor: 5.483

3.  Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.

Authors:  Anita D'Souza; Marcelo Pasquini; Brent Logan; Sergio Giralt; Amrita Krishnan; Joseph Antin; Alan Howard; Stacy Goodman; Muzzafar Qazilbash; Kristin Knust; Firoozeh Sahebi; Daniel Weisdorf; David Vesole; Edward Stadtmauer; David Maloney; Parameswaran Hari
Journal:  Br J Haematol       Date:  2016-06-13       Impact factor: 6.998

Review 4.  Risk Stratification in Multiple Myeloma.

Authors:  Melissa Gaik-Ming Ooi; Sanjay de Mel; Wee Joo Chng
Journal:  Curr Hematol Malig Rep       Date:  2016-04       Impact factor: 3.952

Review 5.  Minimal residual disease analysis in myeloma - when, why and where.

Authors:  Uday Yanamandra; Shaji K Kumar
Journal:  Leuk Lymphoma       Date:  2017-10-11

Review 6.  Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques.

Authors:  Noa Biran; Scott Ely; Ajai Chari
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

7.  Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.

Authors:  Verónica González-Calle; Seila Cerdá; Jorge Labrador; Eduardo Sobejano; Beatriz González-Mena; Carmen Aguilera; Enrique María Ocio; María Belén Vidriales; Noemí Puig; Norma Carmen Gutiérrez; Ramón García-Sanz; José María Alonso; Rosa López; Carlos Aguilar; Alfonso García de Coca; Roberto Hernández; José Mariano Hernández; Fernando Escalante; María-Victoria Mateos
Journal:  Haematologica       Date:  2017-01-25       Impact factor: 9.941

8.  Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.

Authors:  M Michallet; C Chapuis-Cellier; T Dejoie; C Lombard; H Caillon; M Sobh; P Moreau; M Attal; H Avet-Loiseau
Journal:  Leukemia       Date:  2017-06-30       Impact factor: 11.528

9.  The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response.

Authors:  Kazuyuki Shimizu; Yoshikazu Kamiya; Junji Itoh; Jun Okada; Merrell Lim; Satoru Sugiyama
Journal:  Clin Case Rep       Date:  2017-11-28

10.  [The value of serum heavy/light chain immunoassay to assess therapeutic response in patients with multiple myeloma].

Authors:  X C Yu; W Su; J L Zhuang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.